Liposome Drug Delivery Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Liposome Drug Delivery Market is Segmented By Product (Liposomal Paclitaxel, Liposomal Doxorubicin, Liposomal Amphotericin B, and Others), By Technique (Stealth Liposome Technology, Non-PEGylated Liposome Technology, and DepoFoam Liposome Technology), By Indication (Fungal Infections/Diseases, Cancer Therapeutics, Pain Management, Viral Vaccines, and Others), and By Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Liposome Drug Delivery Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: North America
Largest Market: North America
CAGR: 8.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The liposome drug delivery market is expected to register a CAGR of 8.5% during the forecast period of the study, 2022-2027.

Initially, COVID-19 had its impact on the liposome drug delivery market as medical services other than COVID-19, along with research and development activities and logistical operations, were impacted due to the lockdown restrictions around the world by the respective government of the countries. However, soon the importance of liposomes in drug delivery was realized, and intensive research started on the liposome drug delivery system for the treatment of COVID-19 through drugs or vaccines, which is expected to have a significant impact on the growth of the studied market. For instance, according to the research study published by Jingjing Li et al. in November 2021, the researchers developed lyophilized remdesivir liposomes (Rdv-lips), which can be reconstituted as a liposomal aerosol for pulmonary delivery to improve the in vivo behavior of existing remdesivir cyclodextrin conclusion compound (Rdv-cyc) injections and liposome encapsulation endowed remdesivir with much higher solubility and better biocompatibility, and thus, increasing the efficacy of the drug. With companies still engaged in the development of therapeutics against COVID-19, liposome-based drugs or vaccines can play a vital role over the years.

The major factors driving growth in the liposome drug delivery market is the increasing demand for effective and efficient therapeutics owing to the rising burden of chronic diseases such as cancer, diabetes, fungal infections, and others, and liposome-based drug delivery method offers certain advantages over other delivery systems. Thus, drugs are encapsulated into liposomes for effective delivery. For instance, according to the research study published by Peng Liu et al., in February 2022, liposomes have better properties than standard drug delivery methods, such as site-targeting, prolonged or controlled release, drug protection from degradation and clearance, higher therapeutic effects, and lesser toxic side effects, and that's why they are preferred choice of the drug manufacturers. Hence, with the increasing prevalence of chronic diseases around the world, the demand for effective therapeutics is increasing, which is expected to fuel growth in the liposome drug delivery market. For instance, according to the December 2021 update of the International Diabetes Federation, in 2021, about 537 million adults of age 20 to 79 years were living with diabetes around the world, and this number is estimated to reach 643 million by 2030 and 783 million by 2045 which will drive demand for the diabetes therapeutics and hence, driving growth in the studied market.

In addition, the increasing advancement in the liposomal drug delivery method with the new investments in the area along with ongoing research and development activities, product launches, mergers and acquisitions, and collaborations by the key market players is further expected to boost growth in the liposome drug delivery market. For instance, in October 2021, Evonik Health Care, an integrated contract development and manufacturing organization (CDMO) that offers excipients, formulation technologies, and clinical and commercial manufacturing, launched a new version of its established LIPEX liposome extruder. LIPEX Flow meets the market need for more efficient, next-generation high-pressure extruders to produce drug products requiring conventional liposomal drug delivery, including drugs for oncology, vaccines, and other applications.

Further, due to the wide significance of liposomes in drug delivery, many studies and clinical trials are ongoing and positive results from these sources are further expected to have a positive impact on the growth of the studied market. For instance, as per the study "Inhaled Liposomal Antimicrobial Delivery in Lung Infections," published in July 2020, the use of inhaled liposomal antimicrobial treatment in lung Infections results in targeting the antimicrobial agent at the site of infection to the infectious organism, increasing intracellular antibiotic concentrations, reducing drug toxicity, and improving tolerability.

Thus, owing to the above-mentioned factors, the studied market is expected to experience significant growth during the study period. However, stringent regulatory policies for drug approval and side effects associated with drugs are expected to restrain the growth of the liposome drug delivery market during the forecast period of the study.

Scope of the Report

As per the scope of the report, Liposomes are lipid-based bilayer vesicles that can encapsulate, deliver, and release low-soluble drugs and small molecules to a specific target site in the body. They've been shown to help stabilize therapeutic compounds, overcome barriers to cellular and tissue uptake, and improve biodistribution of compounds to target sites in vivo. Liposomes are a desirable delivery technology because of their adaptable physicochemical and biophysical features, which allow for easy customization to meet a variety of delivery needs.

The liposome drug delivery market is segmented by product (liposomal paclitaxel, liposomal Doxorubicin, liposomal Amphotericin B, and others), by technique (stealth liposome technology, non-PEGylated liposome technology, and DepoFoam liposome technology), by indication (fungal infections/diseases, cancer therapeutics, pain management, viral vaccines, and others), and by geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product
Liposomal Paclitaxel
Liposomal Doxorubicin
Liposomal Amphotericin B
Others
By Technique
Stealth Liposome Technology
Non-PEGylated Liposome Technology
DepoFoam Liposome Technology
By Indication
Fungal Infections/Diseases
Cancer Therapeutics
Pain Management
Viral Vaccines
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Cancer Therapeutics is Expected to Account for the Largest Market Share During the Forecast Period

In the indication segment, cancer therapeutics are expected to hold a significant share due to the high prevalence of cancer globally and the rising demand for advanced therapeutics. For instance, according to the research study published by Foad Rammasi and Neda Esfandiari in May 2021, liposomes' high flexibility and capacity for chemical modification by conjugating diverse polymers, ligands, and molecules are a big positive for liposomes in cancer therapeutics, and it not only increases their pharmacological merits but also to boost anticancer treatment effectiveness. Further, as per the same source, liposomes can improve the sensitivity, specificity, and persistence of anti-malignant cell agents in the body, and thus, liposomes are used widely in cancer therapeutics.

In recent years, the burden of cancer around the world has been increasing very rapidly, which is anticipated to fuel growth in the therapeutic cancer segment as cancer is one of the major areas which attracts attention for research and development owing to its severity and high prevalence and thus, the segment is expected to grow over the years. For instance, according to the Globocan 2020 report, approximately 19.3 million new cases of cancer were diagnosed in 2020 globally, with breast cancer being the most prevalent form of cancer, followed by lung cancer. Further, as per the same source, it is estimated that by 2030, about 24.04 million new cancer cases will be diagnosed, which would have a significant impact on the growth of the studied market.

Moreover, new product launches and approvals coupled with partnerships and collaborations, mergers, and acquisitions, by key market players in the area are collectively expected to boost growth in the studied segment. For instance, in June 2020, Ipsen received Fast Track Designation from the United States Food and Drug Administration for the investigational use of liposomal irinotecan (ONIVYDE) in combination with 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) together, known as NALIRIFOX for patients with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC). Thus, new developments like these are further expected to augment growth in the studied segment over the years.

Therefore, due to the high prevalence of cancer, advantages of liposome drug delivery method over others, and new activities by the key market players, the cancer therapeutics segment is expected to hold a major share in the liposome drug delivery market during the forecast period of the study.

Liposome Drug Delivery Market Trends

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the liposome drug delivery market due to the high prevalence of chronic diseases in the region, increasing geriatric population, presence of robust healthcare infrastructure, and some of the key market players in the region. For instance, according to the Globocan 2020 report, in 2020, approximately 2.6 million new cases of cancer were reported in Northern America, and this number is projected to increase to 3.5 million new cancer cases by 2040 in the region. Thus, the demand for therapeutics for cancer is expected to increase in the region, which is expected to drive growth in the studied market in the North American region.

In North America, the United States is expected to hold a major share in the studied market owing to the high prevalence of various chronic diseases, the presence of robust healthcare infrastructure, and research activities in the area. For instance, according to the American Cancer Society’s 2022 report, over 1.9 million new cancer cases with about 609,360 deaths from cancer are expected to be recorded in the United States in 2022. Also, as per the same source, cancer is the second leading cause of death in the United States, and thus, the demand for advanced therapeutics is also high in the country, which is expected to have a positive impact on the growth of the studied market in the country.

Further, there is huge funding provided for research on various diseases in the United States, which is spent on studying the diseases, treatment, and drug delivery systems, and this funding is expected to play a crucial role in the growth of the studied market in the country. For instance, the allocated budget for the National Cancer Institute (United States) for FY 2022 is USD 6.9 billion, which is a USD 353 million net increase over FY 2021, which shows a high level of funding for research and development in the United States, and these fundings are expected to positively affect the market in the country.

Therefore, due to the above-mentioned factors, in North America, the United States is expected to hold a significant market share in the liposome drug delivery market during the forecast period of the study.

Liposome Drug Delivery Market Forecast

Competitive Landscape

The liposome drug delivery market is highly competitive with the presence of several players in the market who are engaged in the development of drugs based on liposome delivery systems. Also, the companies in the area are continuously enhancing their product offering through new launches, collaborations, partnerships, mergers, and acquisitions, which are further expected to increase the competition in the studied market. Some of the key players in the liposome drug delivery market are Gilead Sciences, Inc., Pacira BioSciences, Inc., Luye Pharma Group, Johnson and Johnson, and Ipsen Biopharmaceuticals, Inc., among others.

Recent Development

  • In June 2022, Endo International plc's subsidiary Endo Ventures Limited (EVL) entered into an agreement with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company, to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in phase 3 development for the treatment of osteoarthritis knee pain.
  • In January 2022, Pfizer Inc. and Acuitas Therapeutics entered into a Development and Option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas’ lipid nanoparticle (LNP) technology for up to 10 targets for vaccine or therapeutic development.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Cronic Diseases Like Cancer

      2. 4.2.2 Advancement in the Liposome Drug Delivery Technology and its Higher Efficiency in Drug Delivery

    3. 4.3 Market Restraints

      1. 4.3.1 Regulatory Policies and Adverse Effects Associated with the Drug Delivery

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - in USD Million)

    1. 5.1 By Product

      1. 5.1.1 Liposomal Paclitaxel

      2. 5.1.2 Liposomal Doxorubicin

      3. 5.1.3 Liposomal Amphotericin B

      4. 5.1.4 Others

    2. 5.2 By Technique

      1. 5.2.1 Stealth Liposome Technology

      2. 5.2.2 Non-PEGylated Liposome Technology

      3. 5.2.3 DepoFoam Liposome Technology

    3. 5.3 By Indication

      1. 5.3.1 Fungal Infections/Diseases

      2. 5.3.2 Cancer Therapeutics

      3. 5.3.3 Pain Management

      4. 5.3.4 Viral Vaccines

      5. 5.3.5 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Gilead Sciences, Inc.

      2. 6.1.2 Pacira BioSciences, Inc.

      3. 6.1.3 Spectrum Pharmaceuticals, Inc.

      4. 6.1.4 Takeda Pharmaceutical Company Limited

      5. 6.1.5 Luye Pharma Group

      6. 6.1.6 Johnson and Johnson

      7. 6.1.7 Ipsen Pharma

      8. 6.1.8 Celsion Corporation

      9. 6.1.9 Teva Pharmaceutical Industries Ltd.

      10. 6.1.10 Novartis AG

      11. 6.1.11 Sun Pharmaceutical

      12. 6.1.12 Acrotech Biopharma, Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Liposome Drug Delivery Market market is studied from 2019 - 2027.

The Global Liposome Drug Delivery Market is growing at a CAGR of 8.5% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Gilead Sciences, Inc., Pacira BioSciences, Inc., Luye Pharma Group, Johnson and Johnson, Ipsen Biopharmaceuticals, Inc. are the major companies operating in Global Liposome Drug Delivery Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!